Replies to post #117992 on Biotech Values

[DewDiligence]

Re: Lovenox-vs-Apixaban

That's why primary efficacy endpoints looked at both short-term use (10 ± 4 days) and long-term use (35 ± 4 days).

Nevertheless, the disparate treatment duration of the two drugs adds a confounding element to the data analysis. This is probably a good thing for Lovenox insofar as it makes it harder for the trial to have an unquestionably positive outcome for Apixaban.